Table 5 p53 status and prognosis of esophageal carcinoma: comparison between literature data and the present report
Reference | n | Histology | Treatment | Methods for determining p53 status | Frequency of altered p53 pathway | Prognostic value | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
Antibody | IHC | Sequencing | Function | Overall survival | Event-Free survival | Response | |||||
Ireland [10] | 37 | ACE | Surg | - | - | + | - | 49% (S) | Univariate | NA | NA |
Hagiwara [20] | 42 | SCCE | Surg | + | + | - | - | 28% (Ab) 70% (IHC) | NS | NA | NA |
Ribeiro [9] | 42 | ACE/SCCE | CT-CRT-Surg | - | + | + | - | 59% (IHC) 40% (S) | Univariate (S but not IHC) | Univariate (S but not IHC) | Correlation |
Takahashi [17] | 44 | SCCE | Surg | + | - | - | - | 36% (Ab) | NA | Univariate | NA |
Shimada [21] | 35 | SCCE | Surg | + | + | - | - | 40% (Ab) 54% (IHC) | NA | NA | NA |
Shimada [16] | 110 | SCCE | Surg | + | - | - | - | 36% (Ab) | Multivariate (if p53-Ab disappear post Surg) | NA | NA |
Berqvist [14] | 34 | SCCE/ACE | CRT - CT | + | - | - | - | 21% (Ab) | Multivariate | NA | NA |
Cai [18] | 46 | SCCE | CRT | + | - | - | - | 39% (Ab) | NA | NA | Correlation |
Kihara [8] | 138 | SCCE | Surg | - | - | + | - | 56.5% (S) | Multivariate | NA | Correlation |
Schneider [15] | 59 | ACE | Surg | - | - | + | - | 51% (S) | Multivariate | NA | NA |
Present Study | 84 | SCCE/ACE | CRT +/- Surg | + | - | - | - | 29% (Ab) | Multivariate | Multivariate | NS |